|Dr. Dorothy Helen Bray Ph.D.||Chief Exec. Officer, Pres and Director||21k||N/A||61|
|Mr. James Scott Munro||Chief Financial Officer and Treasurer||20k||N/A||48|
|Dr. Khadija Benlhassan Ph.D.||Chief Scientific Officer and Director||1k||N/A||42|
|Mr. Raymond C. Dabney||Management Consultant||21k||N/A||52|
Immunoclin Corporation provides comprehensive, clinical, and basic science research services to pharmaceutical, biotechnology, and food industries. It is involved in the research and development on products, such as MIRA, an algorithm to analyze the multi-variant data to identify people who are at risk of having heart attack; and GARD, a genetic test for multiple genetic polymorphisms associated with increased risk of the most common form of dementia. Immunoclin Corporation is also engaged in the research and development of PRIMALEUKIN, an antibacterial, anti-fungal, and antiviral agent, harnessing and amplifying the bodys own natural defense against, and recovery from, infection; DACTELLIGENCE, a technology and newly patented concept in bio-sensing to challenge detection platforms in multiple diagnostic fields; and GastroWellBeing, an immunological food supplement. The company was formerly known as Pharma Investing News, Inc. and changed its name to Immunoclin Corporation in December 2013. Immunoclin Corporation is based in Washington, the District of Columbia.
ImmunoClin Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.